PharmPK Discussion - Pharmacologic Tracers

PharmPK Discussion List Archive Index page

On 18 Jan 2000 at 23:05:28, Andy Vandiver (AVandiver.-at-.qualicaps.com) sent the message


Is there any agreement or opinions on which type of pharmacologic tracer
is typically best for testing of patient compliance?

Regards,
Andy Vandiver
Shionogi

Back to the Top

On 20 Jan 2000 at 21:01:39, "Lunnon, Martin W" (mwl12467.aaa.GlaxoWellcome.co.uk) sent the message


Dear Andy,

Morgan Feely (Leeds,UK) has done a lot of work using phenobarb:

Karbwang J. Fungladda W. Pickard CE. Shires S. Hay A. Feely M.
Initial evaluation of low-dose phenobarbital
as an indicator of compliance with antimalarial drug treatment.
Bulletin of the World Health Organization. 76 Suppl
1:67-73, 1998.

  Wolff K. Hay AA. Raistrick D. Feely M. Use of 'very low-dose
phenobarbital' to investigate compliance in
patients on reducing doses of methadone (detoxification). Journal of
Substance Abuse Treatment. 10(5):453-8, 1993
Sep-Oct.

Pullar T. Kumar S. Chrystyn H. Rice P. Peaker S. Feely M. The
prediction of steady-state plasma
phenobarbitone concentrations (following low-dose phenobarbitone) to
refine its use as an indicator of compliance.
British Journal of Clinical Pharmacology. 32(3):329-33, 1991 Sep

Hardy E. Kumar S. Peaker S. Feely M. Pullar T. A comparison of a
short half-life marker (low-dose isoniazid),
a long half-life pharmacological indicator (low-dose phenobarbitone)
and measurements of a controlled release
'therapeutic drug' (metoprolol, Metoros) in reflecting incomplete
compliance by volunteers. British Journal of Clinical
Pharmacology. 30(3):437-41, 1990 Sep.

Peaker S. Mehta AC. Kumar S. Feely M. Measurement of low
(sub-therapeutic) phenobarbitone levels in
plasma by high-performance liquid chromatography: application to
patient compliance studies. Journal of
Chromatography. 497:308-12, 1989 Dec 29.

Penn ND. Peaker S. Griffiths AP. Feely M. Tindall H. Use of a
pharmacological indicator to monitor
compliance with thyroxine. European Journal of Clinical Pharmacology.
35(3):327-9, 1988.

Martin W Lunnon
CVS/Dyslipidaemia Clinical Pharmacology,GWRD, Greenford.
Phone: ..181 966 4456, Fax: ..181 966 4363
E-mail: MWL12467.-a-.glaxowellcome.co.uk

Back to the Top

On 26 Jan 2000 at 00:01:08, "medical" (medical.-a-.wilnetonline.net) sent the message


This would depend on the nature of the study,the evaluation criteria,the
duration of the study,the incentives being offered.
Amit Taneja

Back to the Top

Want to post a follow-up message on this topic? If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Pharmacologic Tracers" as the subject

PharmPK Discussion List Archive Index page